Screening and intervention for subclinical coronary artery disease in patients with type 2 diabetes: THE STENO INTEN-CT STUDY
Key facts
- Where
- Aalborg, Aarhus N, Esbjerg, Herlev, Herning, Hilleroed, Holbæk, Kolding, Nykobing F, Odense C, Silkeborg és Svendborg, DániaSee the 12 sites
- Phase
- 4. fázis
Where in Dánia
- Aalborg University HospitalAalborg, DániaNo longer taking part
- Aarhus University HospitalAarhus N, DániaNo longer taking part
- Sydvestjysk SygehusEsbjerg, DániaNo longer taking part
- Steno Diabetes Center CopenhagenHerlev, DániaNo longer taking part
- Region MidtjyllandHerning, DániaNo longer taking part
- Nordsjaellands HospitalHilleroed, DániaNo longer taking part
- Holbaek SygehusHolbæk, DániaNo longer taking part
- Lillebaelt HospitalKolding, DániaNo longer taking part
- Nykoebing F SygehusNykobing F, DániaNo longer taking part
- Odense University HospitalOdense C, DániaNo longer taking part
- Region MidtjyllandSilkeborg, DániaNo longer taking part
- Odense University HospitalSvendborg, DániaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aarhus University Hospital
- Trial code
- EU 2022-500143-21-01
- Record updated
- 2024. szeptember 20.
- Original description
In type 2 diabetes patients and no known cardiovascular disease, we aim to evaluate the possible cardiovascular benefit of a treatment strategy based on a heart CT scan.Read full original descriptionShow less
In type 2 diabetes patients and no known cardiovascular disease, we aim to evaluate the possible cardiovascular benefit of a treatment strategy based on a heart CT scan.
Inclusion: New or former diagnosis of T2DM according to WHO; Age between 55-69 years (men) and 60-74 years (women); Signed declaration of consent.
Exclusion: Previous history of CVD (previous myocardial infarction or coronary intervention (percutaneous coronary intervention or by-pass), heart failure, stroke or peripheral artery disease as documented by the patient or the patient medical record); Contraindications or allergies to both SGLT2 inhibitors and GLP-1 analogues; Signs of critical cardiac disease: >50% stenosis of left main coronary artery (CT angiography) or left ventricular ejection fraction below 30% (echocardiography). If a CT angiography is not available, a CAC>1000 on the non-contrast cardiac CT will be considered equal to critical cardiac disease; Expected life duration < 1 year for any reason.